Joseph Manni Sells 1,361 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,361 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $32,691.22. Following the completion of the sale, the executive directly owned 55,956 shares of the company’s stock, valued at approximately $1,344,063.12. The trade was a 2.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Performance

Shares of CeriBell stock opened at $23.45 on Thursday. The company has a market capitalization of $900.01 million, a PE ratio of -13.32 and a beta of 0.81. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The stock’s fifty day moving average is $19.89 and its two-hundred day moving average is $19.30.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. BTIG Research upped their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.40.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its holdings in CeriBell by 409.5% during the second quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock worth $143,000 after buying an additional 5,909 shares in the last quarter. Wellington Management Group LLP raised its position in shares of CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. purchased a new stake in shares of CeriBell during the 2nd quarter worth about $603,000. Bank of America Corp DE acquired a new stake in shares of CeriBell during the 2nd quarter valued at about $4,619,000. Finally, PDT Partners LLC purchased a new position in shares of CeriBell in the 2nd quarter valued at about $1,026,000.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.